Risk factors and visual outcome of Non-Arteritic Ischemic Optic Neuropathy (NAION): Experience of a tertiary center in Kuwait
Affiliations
Affiliations
- Al-Bahar Ophthalmology Center, Ibn Sina Hospital, Kuwait, Kuwait.
Abstract
Background: Non-arteritic ischemic optic neuropathy (NAION) is the most common acute optic neuropathy over the age of 50 years. NAION is commonly associated with systemic vascular risk factors (diabetes, hypertension, hyperlipidemia) and small cup-to-disc-ratio. We have assessed the prevalence risk factors of NAION and the visual outcome in patients referred to a tertiary ophthalmology center in Kuwait.
Materials and methods: A retrospective review of new cases of NAION presenting within 2 weeks of onset were included and baseline clinical and demographics characteristic were determined. The prevalence of risk factors and the visual outcome (change in logMAR visual acuity, mean deviation of visual field) was compared between young NAION patients (below 50 years of age) and older NAION patients (over 50 years of age). The odds ratio of a final favorable visual outcome (visual acuity 20/40 or better) by age category was determined.
Results: Seventy-eight eyes of 78 patients with recent onset NAION were included in the study. The most prevalent risk factors for NAION in our subjects were diabetes (64.1%), small cup-to-disc ratio (61.5%), hyperlipidemia (51.3%) and hypertension (38.5%). Young NAION patients had better final logMAR visual acuity (0.55 +- 0.57) then older NAION patients (0.9 +- 0.73), (p = 0.03). Furthermore, young NAION patients were 2.8 times more likely to have a final visual acuity of 20/40 or better than older NAION patients, odds ratio (OR), 2.87; 95% confidence interval (CI), 1.12-7.40, Chi-square p-value = 0.03).
Conclusion: There is a high prevalence of systemic vascular risk factors and small cup-to-disc ratio in NAION patients referred to our center across different age groups (below and above 50 years). Patients below the age of 50 years with NAION are more likely to have a final visual acuity of 20/40 or better than NAION patients above the age of 50 years.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures
Similar articles
Wang YH, Ma J, Gan LY, Zhang X, Wang XQ, Chou YY, Wang XJ, Sun ZZ, Tao ZY, Zhong Y.Zhonghua Yan Ke Za Zhi. 2019 Sep 11;55(9):677-686. doi: 10.3760/cma.j.issn.0412-4081.2019.09.010.PMID: 31495153 Chinese.
Sharma S, Kwan S, Fallano KA, Wang J, Miller NR, Subramanian PS.Ophthalmology. 2017 Apr;124(4):450-455. doi: 10.1016/j.ophtha.2016.11.029. Epub 2016 Dec 22.PMID: 28017420
Non-Arteritic Ischemic Optic Neuropathy Following COVID-19 Vaccination in Korea: A Case Series.
Moon Y, Jung JH, Shin HJ, Choi DG, Park KA, Jeon H, Lee BJ, Kim SJ, Oh SY, Ahn H, Chung SA, Kim US, Lee HJ, Lee JY, Choi YJ; Korean Neuro-Ophthalmology Society.J Korean Med Sci. 2023 Mar 27;38(12):e95. doi: 10.3346/jkms.2023.38.e95.PMID: 36974402 Free PMC article.
Keren S, Zanolli M, Dotan G.BMC Ophthalmol. 2017 Aug 24;17(1):155. doi: 10.1186/s12886-017-0543-y.PMID: 28836961 Free PMC article. Review.
Chatziralli IP, Kazantzis D, Chatzirallis AP, Machairoudia G, Papageorgiou EG, Theodossiadis GP, Psaltopoulou T, Theodossiadis PG, Sergentanis TN.Graefes Arch Clin Exp Ophthalmol. 2022 May;260(5):1445-1456. doi: 10.1007/s00417-021-05522-4. Epub 2022 Jan 24.PMID: 35067769 Review.
Cited by
The Risk of Non-arteritic Ischemic Optic Neuropathy Post-intravitreal Bevacizumab Injection.
Fugara NA, Shawareb ZA, Rakkad NK, Barhoum ML, Shawareb BA, Al-Madani MM, Al-Madani MV.Cureus. 2022 Oct 11;14(10):e30185. doi: 10.7759/cureus.30185. eCollection 2022 Oct.PMID: 36397890 Free PMC article.
COVID-19 Vaccine-Associated Optic Neuropathy: A Systematic Review of 45 Patients.
Elnahry AG, Al-Nawaflh MY, Gamal Eldin AA, Solyman O, Sallam AB, Phillips PH, Elhusseiny AM.Vaccines (Basel). 2022 Oct 20;10(10):1758. doi: 10.3390/vaccines10101758.PMID: 36298623 Free PMC article. Review.
Kemchoknatee P, Singhakul C, Tangon D, Srisombut T.Cureus. 2022 Sep 14;14(9):e29156. doi: 10.7759/cureus.29156. eCollection 2022 Sep.PMID: 36259038 Free PMC article.
Risk of Ocular Adverse Events With Taxane-Based Chemotherapy.
Sodhi M, Yeung SN, Maberley D, Mikelberg F, Etminan M.JAMA Ophthalmol. 2022 Sep 1;140(9):880-884. doi: 10.1001/jamaophthalmol.2022.3026.PMID: 35951320
The Protective Effects of n-Butylidenephthalide on Retinal Ganglion Cells during Ischemic Injury.
Chou YY, Chien JY, Ciou JW, Huang SP.Int J Mol Sci. 2022 Feb 14;23(4):2095. doi: 10.3390/ijms23042095.PMID: 35216208 Free PMC article.
KMEL References
References
-
- Yee RD, Selky AK, Purvin VA. Outcomes of optic nerve sheath decompression for nonarteritic ischemic optic neuropathy. J Neuroophthalmol. 1994;14(2):70–6. - PubMed